Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.83 |
| ▸ | MAOB | P27338 | 2/20 | 0.83 |
| ▸ | CALML3 | P27482 | 6/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24142408 | 1.00 | MAOA (0.83) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL12606373 | 0.93 | MAOA (0.84) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL25759543 | 0.93 | MAOA (0.84) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL1381370 | 0.93 | MAOA (0.84) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL11982920 | 0.92 | MAOA (0.89) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| SCHEMBL12997800 | 0.92 | MAOA (0.89) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL29380875 | 0.91 | MAOA (1.00) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL3807996 | 0.91 | MAOA (1.00) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL440398 | 0.91 | MAOA (1.00) | MAOAMAOBCALML3CYP2C19CYP2C9 | |
| Tedizolid SCHEMBL29833257 | 0.91 | MAOA (1.00) | MAOAMAOBCALML3CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122759-A2 | OXAZOLIDINONE LIPOSOME COMPOSITIONS | AKAGERA MEDICINES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |